Patent intelligence · US
US 6278040
Receptor-deficient mice and cell lines derived therefrom, and uses thereof
Receptor-deficient mice and cell lines derived therefrom, and uses thereof
Patent details — US 6278040
- Jurisdiction
- US
- Status
- expired
- Grant date
- Aug 21, 2001
- Expiration
- Aug 16, 2021
- Applicant
- The Regents of the University of Calif.
- Claims
- 4
- CPC classes
- A61K, A61K31/203, A61K49/0008
Quick answer
US 6278040 (Receptor-deficient mice and cell lines derived therefrom, and uses thereof) is held by The Regents of the University of Calif.. Status: expired. Granted Aug 21, 2001. Expires Aug 16, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- The Regents of the University of Calif.
- Grant date
- Expiration
- Claims
- 4
- CPC classes
- A61K, A61K31/203, A61K49/0008
More from The Regents of the University of Calif.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 6278040?
US 6278040 (Receptor-deficient mice and cell lines derived therefrom, and uses thereof) is held by The Regents of the University of Calif.. Status: expired. Granted Aug 21, 2001. Expires Aug 16, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6278040?
The Regents of the University of Calif. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 6278040 expire?
Our index shows an expiration date of Aug 16, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.